Latest News

NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its American Depositary Shares (“ADSs”), representing ordinary shares, in the Unite

Source link

Related posts

Medical News Today: Can you drink alcohol if you have COPD?


HIMSS20: What’s in it for EMEA changemakers?


LabCorp Latest Testing Company to Be Hacked


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy